Literature DB >> 29439058

Autoimmune necrotising myopathy and HMGCR antibodies.

Kushan Karunaratne1, Dimitri Amiras2, Matthew C Pickering3, Monika Hofer4, Stuart Viegas1.   

Abstract

Statins lower serum cholesterol concentrations by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). Muscle side effects are relatively common and include asymptomatic elevation of serum creatine kinase (CK), myalgia, proximal muscle weakness and rhabdomyolysis. More recently, a subset of cases of immune-mediated necrotising myopathy has been found to have antibodies against HMGCR. It is often an aggressive and debilitating myopathy and has a complex pathogenesis characterised by fibre necrosis, usually with minimal associated inflammation. Not all such patients are taking statins. The general consensus is that best treatment involves withdrawing the statin and giving immunosuppressive and immunomodulatory treatment. We describe three cases of HMGCR-related immune-mediated necrotising myopathy, detailing their clinical course and subsequent management, illustrating the spectrum of this disorder. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  HMG-CoA reductase; autoantibodies; myopathy; necrotizing; statins

Mesh:

Substances:

Year:  2018        PMID: 29439058     DOI: 10.1136/practneurol-2017-001848

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  2 in total

Review 1.  Statin-induced necrotizing autoimmune myopathy: a systematic review.

Authors:  Manoj Kumar Reddy Somagutta; Nishat Shama; Maria Kezia Lourdes Pormento; Ravi Pankajbhai Jagani; Ngaba Neguemadji Ngardig; Klodin Ghazarian; Greta Mahmutaj; Khaled El-Faramawy; Ashwini Mahadevaiah; Molly Sanjay Jain
Journal:  Reumatologia       Date:  2022-02-28

2.  Severe statin-induced autoimmune myopathy successfully treated with intravenous immunoglobulin.

Authors:  Cansu Güngör; Udo Carl Wieshmann
Journal:  BMJ Case Rep       Date:  2020-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.